IL273242B2 - 6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their uses - Google Patents
6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their usesInfo
- Publication number
- IL273242B2 IL273242B2 IL273242A IL27324220A IL273242B2 IL 273242 B2 IL273242 B2 IL 273242B2 IL 273242 A IL273242 A IL 273242A IL 27324220 A IL27324220 A IL 27324220A IL 273242 B2 IL273242 B2 IL 273242B2
- Authority
- IL
- Israel
- Prior art keywords
- disease
- compound
- effective amount
- cancer
- cpt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762558323P | 2017-09-13 | 2017-09-13 | |
| PCT/US2018/050689 WO2019055528A1 (en) | 2017-09-13 | 2018-09-12 | NEW COMPOUND WITH SMALL MOLECULES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL273242A IL273242A (en) | 2020-04-30 |
| IL273242B1 IL273242B1 (en) | 2023-04-01 |
| IL273242B2 true IL273242B2 (en) | 2023-08-01 |
Family
ID=65723058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL273242A IL273242B2 (en) | 2017-09-13 | 2020-03-11 | 6-chloro-3-(4,2-dichloro-5-methoxyphenyl)-2-mercapto-7-methoxyquinazolin-4 (3h)-one and derivative compounds, preparations containing them and their uses |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11186550B2 (https=) |
| EP (1) | EP3681874B1 (https=) |
| JP (1) | JP7170341B2 (https=) |
| KR (1) | KR102644045B1 (https=) |
| CN (1) | CN111372921B (https=) |
| AU (1) | AU2018331371C1 (https=) |
| CA (1) | CA3075649A1 (https=) |
| IL (1) | IL273242B2 (https=) |
| WO (1) | WO2019055528A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3075649A1 (en) | 2017-09-13 | 2019-03-21 | Cerepeut, Inc. | A novel small molecule compound |
| CA3131294A1 (en) * | 2019-02-27 | 2020-09-03 | Cerepeut, Inc. | Quinazolinone compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7368434B2 (en) | 2002-06-27 | 2008-05-06 | The Endowment For Research In Human Biology, Inc. | Compounds useful for the inhibition of ALDH |
| WO2005051974A2 (en) | 2003-06-09 | 2005-06-09 | The Regents Of The University Of California | Novel molecules for regulating cell death |
| AU2006303037A1 (en) | 2005-10-21 | 2007-04-26 | Merz Pharma Gmbh & Co Kgaa | Chromenones and their use as modulators of metabotropic glutamate receptors |
| US9492450B2 (en) * | 2011-04-19 | 2016-11-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of dynamin related protein 1 to promote cell death |
| US8759097B2 (en) * | 2011-04-19 | 2014-06-24 | University of Pittsburgh—of the Commonwealth System of Higher Eduction | Inhibition of dynamin related protein 1 to promote cell death |
| JP2013142070A (ja) | 2012-01-11 | 2013-07-22 | Nihon Univ | ミトコンドリア分裂阻害剤を用いたｔｒａｉｌ抵抗性の克服 |
| CN105008515A (zh) | 2012-12-28 | 2015-10-28 | 小利兰·斯坦福大学托管委员会 | 用于治疗线粒体疾病和用于使细胞分化成神经元的组合物和方法 |
| US9289448B2 (en) | 2013-03-15 | 2016-03-22 | Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for treating alzheimer's disease and other tauopathies |
| US9730935B2 (en) * | 2013-12-13 | 2017-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting a non-canonical notch signaling pathway for cancer treatment |
| GB201522232D0 (en) | 2015-12-16 | 2016-01-27 | Liverpool School Tropical Medicine | Combination product |
| CA3075649A1 (en) | 2017-09-13 | 2019-03-21 | Cerepeut, Inc. | A novel small molecule compound |
-
2018
- 2018-09-12 CA CA3075649A patent/CA3075649A1/en active Pending
- 2018-09-12 CN CN201880070789.4A patent/CN111372921B/zh active Active
- 2018-09-12 KR KR1020207010525A patent/KR102644045B1/ko active Active
- 2018-09-12 JP JP2020515882A patent/JP7170341B2/ja active Active
- 2018-09-12 EP EP18856020.5A patent/EP3681874B1/en active Active
- 2018-09-12 WO PCT/US2018/050689 patent/WO2019055528A1/en not_active Ceased
- 2018-09-12 AU AU2018331371A patent/AU2018331371C1/en active Active
- 2018-09-12 US US16/647,383 patent/US11186550B2/en active Active
-
2020
- 2020-03-11 IL IL273242A patent/IL273242B2/en unknown
-
2021
- 2021-11-29 US US17/537,142 patent/US11912669B2/en active Active
-
2024
- 2024-02-26 US US18/587,753 patent/US12404251B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11186550B2 (en) | 2021-11-30 |
| US11912669B2 (en) | 2024-02-27 |
| KR20200053560A (ko) | 2020-05-18 |
| US20220340534A1 (en) | 2022-10-27 |
| JP2020533399A (ja) | 2020-11-19 |
| AU2018331371A1 (en) | 2020-04-02 |
| AU2018331371C1 (en) | 2024-05-09 |
| CN111372921B (zh) | 2023-12-01 |
| US12404251B2 (en) | 2025-09-02 |
| IL273242A (en) | 2020-04-30 |
| KR102644045B1 (ko) | 2024-03-05 |
| IL273242B1 (en) | 2023-04-01 |
| JP7170341B2 (ja) | 2022-11-14 |
| EP3681874A1 (en) | 2020-07-22 |
| WO2019055528A1 (en) | 2019-03-21 |
| AU2018331371B2 (en) | 2024-02-15 |
| EP3681874B1 (en) | 2022-04-06 |
| EP3681874A4 (en) | 2021-01-13 |
| CN111372921A (zh) | 2020-07-03 |
| US20240246919A1 (en) | 2024-07-25 |
| US20200216400A1 (en) | 2020-07-09 |
| CA3075649A1 (en) | 2019-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Adhihetty et al. | Effect of denervation on mitochondrially mediated apoptosis in skeletal muscle | |
| US12404251B2 (en) | Small molecule compound | |
| Mamedov et al. | New tetrahydro-isoquinoline derivatives as cholinesterase and α-glycosidase inhibitors: Synthesis, characterization, molecular docking & dynamics, ADME prediction, in vitro cytotoxicity and enzyme inhibition studies | |
| JPH11514643A (ja) | ロタマーゼ酵素活性阻害剤 | |
| CN101631547A (zh) | 使用地莫本和多奈哌齐治疗阿尔茨海默病的组合疗法 | |
| IL305332A (en) | A combination of ABT-199 and achmetalstat for the treatment of AML | |
| JPH08502488A (ja) | 前立腺癌および初期神経悪性疾患に対するベンゾキノイドアンサマイシンの殺腫瘍活性 | |
| Yajing et al. | Approved drugs and natural products at clinical stages for treating Alzheimer’s disease | |
| Kumar et al. | Optimization of B-ring-functionalized antimalarial tambjamines and prodiginines | |
| Zhang et al. | 13-methylpalmatine alleviates myocardial ischemia/reperfusion injury by potentially targeting the C5a-C5aR1 axis to inhibit neutrophil extracellular trap formation | |
| CN114874220B (zh) | 一种8-胺基苯磺酰胺取代的色胺酮类衍生物及其制备和应用 | |
| KR20100116177A (ko) | 근골격-관련 장애의 치료에서 헤지호그 효능제의 용도 | |
| Liu et al. | Protective Effect of Topiroxostat on Myocardial Injury Induced by Lipopolysaccharide | |
| IL299761A (en) | GABAA alpha 5 agonist polymorphs and methods of use for the treatment of cognitive impairment | |
| US12589090B2 (en) | Compounds and methods for the treatment of degenerative disorders | |
| Pang et al. | A Novel Oxo‐Palmatine Derivative 2q as Potent Reversal Agents Against Alzheimer's Disease | |
| Poshyvak et al. | The synergy of antiepileptic action of combined usage of neuro-vascular modulators with a wide spectrum of effects upon neuronal tissue | |
| Okkay et al. | Pharmacological, Non-Pharmacological Management, and Emerging Therapies for the Management of Alzheimer's Disease | |
| IL322808A (en) | Quinoline derivatives used as kappa-opioid receptor agonists | |
| Muthuraman et al. | Current Perspectives in the Management of Neurodegenerative Alzheimer’s Disease: Preclinical and Clinical Status | |
| IL313615A (en) | Use of a class of 1,4-dihydro-naphthyridine derivatives in treatment of tumors | |
| IL314334A (en) | Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug |